Pyrazolone-derivatives and their use as PDE-4 inhibitors
The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.
1. 5-(3,4-Dimethoxyphenyl)-2-{1-[(5-hydroxy-2-methyl-phenyl)carbonyl]piperidin-4-yl}-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one or a salt thereof.
2. 5-(3,4-Dimethoxyphenyl)-2-{1-[(5-hydroxy-2-methyl-phenyl)carbonyl]piperidin-4-yl}-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one.
3. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable auxiliary.
4. A pharmaceutical composition comprising the compound according to claim 2 , together with at least one pharmaceutically acceptable auxiliary.
5. A method of treating a disease selected from the group consisting of bronchitis, allergic bronchitis, bronchial asthma, emphysema, COPD, pulmonary hypertension, lung fibrosis and allergic rhinitis comprising administering to a patient a therapeutically effective amount of a compound of claim 1 .
6. A method of treating a disease selected from the group consisting of bronchitis, allergic bronchitis, bronchial asthma, emphysema, COPD, pulmonary hypertension, lung fibrosis and allergic rhinitis comprising administering to a patient a therapeutically effective amount of a compound of claim 2 .
7. The method of treating psoriasis or atopic dermatitis comprising administering to a patient a therapeutically effective amount of a compound of claim 1 .
8. The method of treating psoriasis or atopic dermatitis comprising administering to a patient a therapeutically effective amount of a compound of claim 2 .